It has been suggested that aim of the temporal lobe epilepsy surgery is twofold: first is to decrease seizure frequency and second is to improve quality of life without causing intolerable complications. The aim of this prospective, longitudinal clinical study is to report outcomes with respect to seizure, medication, employment and quality of life in short- and long-term follow-ups after resective temporal lobe epilepsy surgery. Consecutively 63 patients who underwent resective temporal lobe epilepsy surgery between 1993 and 1994 were enrolled. Outcomes at 6 months, 2 and 12 years were evaluated and compared with pre-operative status. The mean follow-up of this study was 12.3+/-0.6 years. Results showed that rates of seizure freedom were 82.5, 76.2, and 70.8% at 6 months, 2 and 12 years, respectively. Significant reduction in antiepileptic drug dose at long-term follow-up was found when compared to baseline. Patients after surgery had net gain of employment and improved quality of life was seen in all seizure outcome groups after surgery. Seizure-free patients showed better quality of life than those who continued to have seizure. Our results suggest that surgery leads to improvement in both seizure outcome and quality of life. Even years after the surgery, patients are still working, have reduced their medication load and have nearly normal life.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.seizure.2007.11.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to amyloid-beta (Aβ) protofibrils, was formally evaluated as a treatment for early Alzheimer's disease in a phase 2 study (Study 201) and the phase 3 Clarity AD study. These trials both included an 18-month, randomized study (core) and an open-label extension (OLE) phase where eligible participants received open-label lecanemab for up to 30 months to date. Clinical (CDR-SB, ADAS-Cog14, and ADCS-MCI-ADL), biomarker (PET, Aβ42/40 ratio, and ptau181) and safety outcomes were evaluated.
View Article and Find Full Text PDFAlzheimer's disease pathophysiology is believed to involve various abnormalities, including those of amyloid beta (Ab) peptide and tau processing, inflammation, oxidative stress, and vascular risk factors. Aβ peptides exist in a dynamic continuum of conformational states from monomeric Aβ, to soluble progressively larger Aβ assemblies that include a range of low molecular weight oligomers to higher molecular weight protofibrils, and finally to insoluble fibrils (plaques). Various lines of evidence support the "amyloid hypothesis" that Aβ plays a central role in the pathogenesis of AD, and several immunotherapies have been developed to interact with this cascade in various different places which may reduce the number of soluble aggregates and insoluble Aβ fibrils deposited in the brain.
View Article and Find Full Text PDFBackground: Lecanemab is an approved anti-amyloid monoclonal antibody that binds with highest affinity to soluble Aβ protofibrils, which are more toxic than monomers or insoluble fibrils/plaque. In clinical studies, biweekly lecanemab treatment demonstrated a slowing of decline in clinical (global, cognitive, functional, and quality of life) outcomes, and reduction in brain amyloid in early Alzheimer's disease (AD). Herein, we describe the impact of lecanemab treatment on tau PET.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Stevenson University, Owings Mills, MD, USA.
Background: Most assisted living (AL) settings organize and provide opportunities for residents to participate in activities (e.g., exercise, music, arts and craft, cognitive activities, religious services, community outings).
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
University College London, London, United Kingdom.
Background: The progressive nature of dementia and the complex needs means that people living with dementia require tailored approaches to address their changing care needs over time. These include physical multimorbidity, psychological, behavioural, and cognitive symptoms and possible risks arising from these and helping family caregivers. However, provision of these interventions is highly variable between and within countries, partly due to uncertainty about their efficacy and scarce resources.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!